Recent briefings through late June 2026 did not identify discrete Pfizer-specific corporate news events in the 30 days preceding this report's generation date of 2026-07-19. The broader macro environment over this period was characterised by heightened geopolitical uncertainty, which formed the backdrop against which Pfizer's publicly available data was reviewed. No Pfizer-specific material announcements, regulatory decisions, or litigation outcomes were recorded in the sourced briefings during this window [Brief - 2026-07-11] [Brief - 2026-07-03] [Brief - 2026-06-25].
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent filing period, representing year-over-year revenue growth of 5.37%. Net income over the same period was $7.49 billion, producing a net margin of 11.83%. Operating margin was recorded at 35.40%. Earnings per share declined 9.62% year-over-year. The company carried $64.46 billion in total debt against $1.70 billion in cash, and the stock traded at a price-to-earnings ratio of 19.12 [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data reflects material position changes across several prominent filers. Citadel reduced its PFE position by 17%, while AQR Capital added 21% to its existing position and Millennium added 9.9%. These changes represent the primary trigger for this report. No insider transactions via SEC Form 4 filings were included in the data provided for this reporting period [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026].
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.57% and the 2-year yield at 4.16%, producing a normal yield curve with a spread of 41 basis points [FRED DGS10] [FRED DGS2]. This rate configuration forms part of the broader financial context in which Pfizer's balance sheet, which carries substantial long-term debt, is being assessed by market participants.